TSW
CRVO icon

Thompson Siegel & Walmsley’s CervoMed CRVO Stock Holding History

Thompson Siegel & Walmsley’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed -$1K – 794
2018
Q1 		$1K Hold
2
– – ﹤0.01% 779
2017
Q4 		$2K Buy
+2
New +$3.24K ﹤0.01% 807

Other funds holding CRVO

SRCM
Swift Run Capital Management Charlottesville, Virginia $51.8M AUM 6.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
SFM
Signature Financial Management Norfolk, Virginia $416M AUM 8.59% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Thompson Siegel & Walmsley's CRVO Position: Q2 2018 in Review

Thompson Siegel & Walmsley sold out of CervoMed (CRVO) in Q2 2018, closing a stake of 2 shares — an estimated $1K sold.

Thompson Siegel & Walmsley first reported a position in CRVO in Q4 2017 and held it in 2 quarters. The position peaked at $2K in Q4 2017. 14 funds tracked by Wall St. Rank hold CRVO as of Q2 2018.

  • Thompson Siegel & Walmsley reported no remaining CervoMed position as of Q2 2018 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 2 CervoMed shares in Q2 2018, an estimated $1K.
  • Thompson Siegel & Walmsley first reported a position in CervoMed in Q4 2017 and held it in 2 quarters.
  • Thompson Siegel & Walmsley's CervoMed position peaked at $2K in Q4 2017.
  • 14 funds tracked by Wall St. Rank held CervoMed as of Q2 2018.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2018, filed 9 Aug 2018.